Analysed CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) News Sources
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
02-10-2025
yahoo.com
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
14-10-2025
yahoo.com
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
06-11-2025
yahoo.com
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
18-11-2025
yahoo.com
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
08-12-2025
yahoo.com
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
13-01-2026
yahoo.com
What is the current price of CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ)?
The current price of CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) is $1.17.
CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) absolute price change since previous trading day?
The absolute price change of CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) since the previous trading day is $0.03.
CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) percentage price change since previous trading day?
The percentage price change of CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) since the previous trading day is 2.6316%.
What is the most recent average sentiment score for CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ)?
The most recent average sentiment score for CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ)?
The most recent sentiment for CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ) is .
SEC-8K** Filing Available For CYTOMED THERAPEUTICS LTD (GDTC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.